Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies

Journal of Neural Transmission

Volumn 122, Issue 4, 2015, Pages 607-617

  Dai, Chun Ling ^a   Chen, Xia ^a   Kazim, Syed Faraz ^a,b,c   Liu, Fei ^a   Gong, Cheng Xin ^a   Grundke Iqbal, Inge ^a   Iqbal, Khalid ^a  

^a Inge Grundke Iqbal Research Floor New York State Institute for Basic Research in Developmental Disabilities ^*  (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c SUNY IBR Center for Developmental Neuroscience (CDN)   (United States)

Author keywords

Alzheimer s disease; A ; Immunotherapy; Tau; Tauopathy

Indexed keywords

ALZHEIMER DISEASE VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 43D; MONOCLONAL ANTIBODY 77 E9; NOOTROPIC AGENT; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID PRECURSOR PROTEIN; ANTIBODY; APP PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; AMYGDALOID NUCLEUS; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; BODY WEIGHT; BRAIN CORTEX; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIPPOCAMPAL CA1 REGION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MORRIS WATER MAZE TEST; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REFERENCE MEMORY; SPATIAL LEARNING; SUBICULUM; TAUOPATHY; TREATMENT DURATION; WESTERN BLOTTING; ANIMAL; CHEMISTRY; COGNITION DISORDERS; COMPLICATION; DISEASE MODEL; GENETICS; IMMUNOLOGY; MAZE TEST; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PLAQUE, AMYLOID; PROCEDURES; PSYCHOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; MAZE LEARNING; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PLAQUE, AMYLOID; PRESENILIN-1; TAU PROTEINS;

EID: 84926177873     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-014-1315-y     Document Type: Article

References (61)

1. Alafuzoff I, Iqbal K, Friden H, Adolfsson R, Winblad B (1987) Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol (Berl) 74:209–225
2. Alonso AD, Zaidi T, Grundke-Iqbal I, Iqbal K (1994) Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA 91:5562–5566
3. Alonso AD, Grundke-Iqbal I, Iqbal K (1996) Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 2:783–787
4. Amadoro G, Serafino AL, Barbato C, Ciotti MT, Sacco A, Calissano P, Canu N (2004) Role of N-terminal tau domain integrity on the survival of cerebellar granule neurons. Cel Death Differ 11:217–230. doi:10.1038/sj.cdd.4401314
5. Amadoro G, Ciotti MT, Costanzi M, Cestari V, Calissano P, Canu N (2006) NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proc Natl Acad Sci USA 103:2892–2897. doi:10.1073/pnas.0511065103
6. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 42:631–639
7. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27:9115–9129
8. Avila J, Simon D, Diaz-Hernandez M, Pintor J, Hernandez F (2014) Sources of extracellular tau and its signaling. J Alzheimers Dis 40(Suppl 1):S7–S15. doi:10.3233/JAD-131832
9. Bensadoun A, Weinstein D (1976) Assay of proteins in the presence of interfering materials. Anal Biochem 70:241–250
10. Bi M, Ittner A, Ke YD, Gotz J, Ittner LM (2011) Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 6:e26860. doi:10.1371/journal.pone.0026860
11. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H (2010) Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 224:472–485. doi:10.1016/j.expneurol.2010.05.010
12. Boutajangout A, Quartermain D, Sigurdsson EM (2010) Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 30:16559–16566. doi:10.1523/JNEUROSCI.4363-10.2010
13. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM (2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118:658–667. doi:10.1111/j.1471-4159.2011.07337.x
14. Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18:351–357
15. Braak H, Zetterberg H, Del Tredici K, Blennow K (2013) Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-beta changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol 126:631–641. doi:10.1007/s00401-013-1139-0
16. Castillo-Carranza DL et al (2014) Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci 34:4260–4272. doi:10.1523/JNEUROSCI.3192-13.2014
17. Chai X et al (2011) Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 286:34457–34467. doi:10.1074/jbc.M111.229633
18. Clavaguera F et al (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11:909–913
19. Clavaguera F et al (2013) Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci USA 110:9535–9540. doi:10.1073/pnas.1301175110
20. Clinton LK et al (2007) Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Neurobiol Dis 28:76–82
21. Corsetti V et al (2008) Identification of a caspase-derived N-terminal tau fragment in cellular and animal Alzheimer’s disease models. Mol Cell Neurosci 38:381–392. doi:10.1016/j.mcn.2008.03.011
22. d’Abramo C, Acker CM, Jimenez HT, Davies P (2013) Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One 8:e62402. doi:10.1371/journal.pone.0062402
23. Denk F, Wade-Martins R (2009) Knock-out and transgenic mouse models of tauopathies. Neurobiol Aging 30:1–13. doi:10.1016/j.neurobiolaging.2007.05.010
24. D’Hooge R, De Deyn PP (2001) Applications of the Morris water maze in the study of learning and memory. Brain Res Brain Res Rev 36:60–90
25. Doody RS et al (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 370:311–321. doi:10.1056/NEJMoa1312889
26. Flight MH (2013) Neurodegenerative disease: tau immunotherapy targets transcellular propagation. Nat Rev Drug Discov 12:904. doi:10.1038/nrd4179
27. Frost B, Jacks RL, Diamond MI (2009) Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284:12845–12852. doi:10.1074/jbc.M808759200
28. Garg S, Timm T, Mandelkow EM, Mandelkow E, Wang Y (2011) Cleavage of Tau by calpain in Alzheimer’s disease: the quest for the toxic 17 kD fragment. Neurobiol Aging 32:1–14. doi:10.1016/j.neurobiolaging.2010.09.008
29. Giacobini E, Gold G (2013) Alzheimer disease therapy-moving from amyloid-beta to tau. Nat Rev Neurol. doi:10.1038/nrneurol.2013.223
30. Giannakopoulos P et al (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology 60:1495–1500
31. Glenner GG, Wong CW (1984) Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885–890
32. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83:4913–4917
33. Gu J, Congdon EE, Sigurdsson EM (2013) Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J Biol Chem 288:33081–33095. doi:10.1074/jbc.M113.494922
34. Holmes C et al (2008) Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216–223
35. Iqbal K et al (1986) Defective brain microtubule assembly in Alzheimer’s disease. Lancet 2:421–426
36. Kazim SF, Blanchard J, Dai CL, Tung YC, LaFerla FM, Iqbal IG, Iqbal K (2014) Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer’s disease. Neurobiol Dis. doi:10.1016/j.nbd.2014.07.001
37. Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I (1993) Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem 268:24374–24384
38. Lambracht-Washington D, Rosenberg RN (2013) Anti-amyloid beta to tau-based immunization: developments in immunotherapy for Alzheimer disease. Immuno Targets Ther 2013:105–114. doi:10.2147/ITT.S31428
39. Mandelkow EM, Schweers O, Drewes G, Biernat J, Gustke N, Trinczek B, Mandelkow E (1996) Structure, microtubule interactions, and phosphorylation of tau protein. Ann N Y Acad Sci 777:96–106
40. Masliah E et al (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron 46:857–868. doi:10.1016/j.neuron.2005.05.010
41. Morris RG, Garrud P, Rawlins JN, O’Keefe J (1982) Place navigation impaired in rats with hippocampal lesions. Nature 297:681–683
42. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM (2003a) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol Aging 24:1063–1070
43. Oddo S et al (2003b) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:409–421
44. Park SY, Ferreira A (2005) The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration. J Neurosci 25:5365–5375. doi:10.1523/JNEUROSCI.1125-05.2005
45. Reinecke JB et al (2011) Implicating calpain in tau-mediated toxicity in vivo. PloS One 6:e23865. doi:10.1371/journal.pone.0023865
46. Reitz C (2012) Alzheimer’s disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis 2012:369808. doi:10.1155/2012/369808
47. Roberson ED et al (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science 316:750–754
48. Rosario ER, Carroll JC, Oddo S, LaFerla FM, Pike CJ (2006) Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer’s disease. J Neurosci 26:13384–13389. doi:10.1523/JNEUROSCI.2514-06.2006
49. Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, Abramsky O (2006) Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 63:1459–1467. doi:10.1001/archneur.63.10.1459
50. Salloway S et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 370:322–333. doi:10.1056/NEJMoa1304839
51. Sanders DW et al (2014) Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82:1271–1288. doi:10.1016/j.neuron.2014.04.047
52. Sigurdsson EM (2008) Immunotherapy targeting pathological tau protein in Alzheimer’s disease and related tauopathies. J Alzheimers Dis 15:157–168
53. Terry RD et al (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572–580
54. Thies W, Bleiler L, Alzheimer’s A (2013) 2013 Alzheimer’s disease facts and figures. Alzheimers Dement 9:208–245. doi:10.1016/j.jalz.2013.02.003
55. Tomlinson BE, Blessed G, Roth M (1970) Observations on the brains of demented old people. J Neurol Sci 11:205–242
56. Troquier L et al (2012) Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 9:397–405
57. Vallet PG, Guntern R, Hof PR, Golaz J, Delacourte A, Robakis NK, Bouras C (1992) A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer’s disease. Acta Neuropathol 83:170–178
58. Vorhees CV, Williams MT (2006) Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1:848–858. doi:10.1038/nprot.2006.116
59. Winblad B, Graf A, Riviere ME, Andreasen N, Ryan JM (2014) Active immunotherapy options for Alzheimer’s disease. Alzheimers Res Ther 6:7. doi:10.1186/alzrt237
60. Yanamandra K et al (2013) Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80:402–414. doi:10.1016/j.neuron.2013.07.046
61. Zilka N, Kontsekova E, Novak M (2008) Chaperone-like antibodies targeting misfolded tau protein: new vistas in the immunotherapy of neurodegenerative foldopathies. J Alzheimers Dis 15:169–179